Vor Biopharma Inc. (NASDAQ:VOR) is identified as one of the hot penny stocks to invest in, with an analyst upgrading the company to a Buy rating and a price target of $3.00. The company has entered into an exclusive license agreement with RemeGen Co. for the development and commercialization of telitacicept in regions outside of Greater China. Telitacicept, a recombinant fusion protein, has shown clinical success and gained marketing approvals in China for various conditions. The agreement with RemeGen Co. provides Vor Biopharma Inc. financial strength through upfront and potential milestone payments, supporting its growth in the clinical-stage cell therapy sector targeting cancer treatment.

Read more at Yahoo Finance: H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target